Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Mol Pharmacol
2012 Aug 01;822:344-59. doi: 10.1124/mol.112.078568.
Show Gene links
Show Anatomy links
Mapping the binding of GluN2B-selective N-methyl-D-aspartate receptor negative allosteric modulators.
Burger PB
,
Yuan H
,
Karakas E
,
Geballe M
,
Furukawa H
,
Liotta DC
,
Snyder JP
,
Traynelis SF
.
???displayArticle.abstract???
We have used recent structural advances in our understanding of the N-methyl-d-aspartate (NMDA) receptor amino terminal domain to explore the binding mode of multiple diaryl GluN2B-selective negative allosteric modulators at the interface between the GluN1 and GluN2B amino-terminal domains. We found that interaction of the A ring within the binding pocket seems largely invariant for a variety of structurally distinct ligands. In addition, a range of structurally diverse linkers between the two aryl rings can be accommodated by the binding site, providing a potential opportunity to tune interactions with the ligand binding pocket via changes in hydrogen bond donors, acceptors, as well as stereochemistry. The most diversity in atomic interactions between protein and ligand occur in the B ring, with functional groups that contain electron donors and acceptors providing additional atomic contacts within the pocket. A cluster of residues distant to the binding site also control ligand potency, the degree of inhibition, and show ligand-induced increases in motion during molecular dynamics simulations. Mutations at some of these residues seem to distinguish between structurally distinct ligands and raise the possibility that GluN2B-selective ligands can be divided into multiple classes. These results should help facilitate the development of well tolerated GluN2B subunit-selective antagonists.
Akazawa,
Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats.
1994, Pubmed
Akazawa,
Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats.
1994,
Pubmed
Auffinger,
Halogen bonds in biological molecules.
2004,
Pubmed
Avenet,
Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytes.
1996,
Pubmed
,
Xenbase
Barta-Szalai,
Oxamides as novel NR2B selective NMDA receptor antagonists.
2004,
Pubmed
Bowers,
The midpoint method for parallelization of particle simulations.
2006,
Pubmed
Butler,
(3R,4S)-3-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]chroman-4,7-diol: a conformationally restricted analogue of the NR2B subtype-selective NMDA antagonist (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)- 1-propanol.
1998,
Pubmed
Carter,
Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties.
1988,
Pubmed
Chenard,
Antagonists selective for NMDA receptors containing the NR2B subunit.
1999,
Pubmed
Chenard,
Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.
1991,
Pubmed
Chenard,
(1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses.
1995,
Pubmed
Citri,
Synaptic plasticity: multiple forms, functions, and mechanisms.
2008,
Pubmed
Clark,
Halogen bonding: the sigma-hole. Proceedings of "Modeling interactions in biomolecules II", Prague, September 5th-9th, 2005.
2007,
Pubmed
Coyle,
Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia.
2003,
Pubmed
Edgar,
MUSCLE: a multiple sequence alignment method with reduced time and space complexity.
2004,
Pubmed
Farina,
Separation of domain contacts is required for heterotetrameric assembly of functional NMDA receptors.
2011,
Pubmed
Fischer,
Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro.
1997,
Pubmed
,
Xenbase
Gallagher,
Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor.
1996,
Pubmed
Gielen,
Mechanism of differential control of NMDA receptor activity by NR2 subunits.
2009,
Pubmed
Gill,
Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist.
2002,
Pubmed
,
Xenbase
Gotti,
Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia.
1988,
Pubmed
Hallett,
Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
2004,
Pubmed
Hansen,
Control of assembly and function of glutamate receptors by the amino-terminal domain.
2010,
Pubmed
Hansen,
Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists.
2010,
Pubmed
,
Xenbase
Hardingham,
Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders.
2010,
Pubmed
Hashimoto,
Interactions of erythro-ifenprodil, threo-ifenprodil, erythro-iodoifenprodil, and eliprodil with subtypes of sigma receptors.
1995,
Pubmed
Humphrey,
VMD: visual molecular dynamics.
1996,
Pubmed
Imai,
Cl-pi interactions in protein-ligand complexes.
2008,
Pubmed
Karakas,
Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors.
2011,
Pubmed
,
Xenbase
Karakas,
Structure of the zinc-bound amino-terminal domain of the NMDA receptor NR2B subunit.
2009,
Pubmed
,
Xenbase
Kew,
A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones.
1996,
Pubmed
Kobayashi,
Inhibition of G protein-activated inwardly rectifying K+ channels by ifenprodil.
2006,
Pubmed
,
Xenbase
Koller,
Novel N-methyl-D-aspartate receptor antagonists: a review of compounds patented since 2006.
2010,
Pubmed
Kumar,
The N-terminal domain of GluR6-subtype glutamate receptor ion channels.
2009,
Pubmed
Kumar,
Structure and assembly mechanism for heteromeric kainate receptors.
2011,
Pubmed
,
Xenbase
Laskowski,
PDBsum new things.
2009,
Pubmed
Low,
Molecular determinants of proton-sensitive N-methyl-D-aspartate receptor gating.
2003,
Pubmed
,
Xenbase
Marinelli,
Homology modeling of NR2B modulatory domain of NMDA receptor and analysis of ifenprodil binding.
2007,
Pubmed
Masuko,
A regulatory domain (R1-R2) in the amino terminus of the N-methyl-D-aspartate receptor: effects of spermine, protons, and ifenprodil, and structural similarity to bacterial leucine/isoleucine/valine binding protein.
1999,
Pubmed
,
Xenbase
Matter,
Evidence for C-Cl/C-Br...pi interactions as an important contribution to protein-ligand binding affinity.
2009,
Pubmed
McCauley,
NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles.
2004,
Pubmed
Mony,
Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential.
2009,
Pubmed
Mony,
Structural basis of NR2B-selective antagonist recognition by N-methyl-D-aspartate receptors.
2009,
Pubmed
,
Xenbase
Monyer,
Developmental and regional expression in the rat brain and functional properties of four NMDA receptors.
1994,
Pubmed
Mosley,
Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors.
2009,
Pubmed
,
Xenbase
Mosley,
Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-methyl-D-aspartate receptor antagonists.
2010,
Pubmed
,
Xenbase
Mott,
Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition.
1998,
Pubmed
,
Xenbase
Nagy,
Inducible expression and pharmacology of recombinant NMDA receptors, composed of rat NR1a/NR2B subunits.
2003,
Pubmed
Perin-Dureau,
Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors.
2002,
Pubmed
,
Xenbase
Preskorn,
An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
2008,
Pubmed
Reisberg,
Memantine in moderate-to-severe Alzheimer's disease.
2003,
Pubmed
Roberts,
MultiSeq: unifying sequence and structure data for evolutionary analysis.
2006,
Pubmed
Sali,
Derivation of rules for comparative protein modeling from a database of protein structure alignments.
1994,
Pubmed
Sobolevsky,
X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor.
2009,
Pubmed
Tahirovic,
Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists.
2008,
Pubmed
,
Xenbase
Tamiz,
N-(2-(4-hydroxyphenyl)ethyl)-4-chlorocinnamide: a novel antagonist at the 1A/2B NMDA receptor subtype.
1998,
Pubmed
Traynelis,
Glutamate receptor ion channels: structure, regulation, and function.
2010,
Pubmed
Williams,
Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors.
1993,
Pubmed
,
Xenbase
Wright,
Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalkynyl)-4-benzylpiperidines.
2000,
Pubmed
,
Xenbase
Wu,
Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain.
2009,
Pubmed
Yuan,
Control of NMDA receptor function by the NR2 subunit amino-terminal domain.
2009,
Pubmed
,
Xenbase
Zhao,
Analysis of high-affinity assembly for AMPA receptor amino-terminal domains.
2012,
Pubmed
